Satellos completes enrollment in BASECAMP Phase 2 trial of forazapadin for Duchenne
The company said topline data from the trial will now come in the first quarter of 2027 after adjusting its prior data release plan.
SEC filing
Latest
2 stories
Yesterday
Thursday, September 24
Satellos gets FDA clearance for forazapadin IND in FSHD
The FDA cleared Satellos Bioscience's IND for forazapadin in facioscapulohumeral muscular dystrophy, with the FSHD Canada Foundation providing up to $5 million in non-dilutive funding for a planned Phase 2 study.
SEC filing